In a real-world US study of 2,247 type 2 diabetes patients, tirzepatide brought 69% to target blood sugar levels and produced average weight loss of 6.3 kg at 6 months, with even better results in patients new to GLP-1 drugs.
69% achieved HbA1c <7%In real-world US practice, more than two-thirds of type 2 diabetes patients starting tirzepatide reached the recommended blood sugar target within 6 months
What the researchers found
At 6-month follow-up, 69% of the overall cohort achieved HbA1c <7%, rising to 77% in the GLP-1 RA-naïve subgroup. Mean weight changes by subgroup were:
- Overall cohort: -6.3 kg
- Baseline HbA1c <7%: -7.1 kg
- GLP-1 RA-naïve: -8.1 kg
More pronounced HbA1c reductions occurred in GLP-1 RA-naïve patients and those with higher baseline HbA1c (≥7%), while greater weight loss was seen in GLP-1 RA-naïve patients and those with lower baseline HbA1c (<7%). The cohort was 58% female, mean age 54, and 54% were already on a GLP-1 RA at baseline.
Why it matters
Clinical trials showed tirzepatide's impressive efficacy, but real-world data is essential to confirm these benefits hold up in everyday practice — where patients may have more comorbidities, take different medications, and adhere less perfectly. This study confirms that tirzepatide delivers meaningful blood sugar control and weight loss in routine clinical care.
How the study worked
Observational, single-cohort, pre-post study using the Healthcare Integrated Research Database (HIRD). Researchers identified commercially insured US adults (≥18 years) with type 2 diabetes who initiated tirzepatide between May 2022 and January 2023 and had HbA1c measurements at baseline and 6-month follow-up. Key outcomes (HbA1c and weight) were assessed overall and in subgroups by baseline GLP-1 RA use and HbA1c level.
What this study cannot tell us
This is an observational study without a control group, so improvements cannot be definitively attributed to tirzepatide alone. The study used commercial insurance claims data, which may not represent uninsured or Medicare/Medicaid populations. Only 6 months of follow-up was assessed, and the cohort was predominantly non-Hispanic White. Adherence and persistence data were not detailed.
How to read the evidence
This is a real-world observational cohort study using commercial insurance claims data. While it provides valuable evidence of effectiveness in routine clinical practice, it lacks a control group and randomization, making it lower evidence than the randomized controlled SURPASS trials.
When this study was published
Published in 2025, this is among the earliest real-world evidence for tirzepatide, which was approved in May 2022. The data captures the first wave of real-world use.
The bigger picture
Tirzepatide, a dual GIP/GLP-1 receptor agonist, represents the next generation of incretin-based therapies. This real-world evidence complements clinical trial data and helps build the case for broader use, including in patients switching from other GLP-1 drugs. The finding that GLP-1-naïve patients benefit most has practical implications for treatment sequencing decisions.
Questions still open
- How does real-world tirzepatide performance compare directly to real-world semaglutide outcomes in similar populations?
- Do the blood sugar and weight loss benefits of tirzepatide persist or increase beyond 6 months in real-world settings?
- Why do GLP-1 RA-naïve patients respond better — is this a biological effect or related to higher motivation in treatment-new patients?
Common questions
Does tirzepatide work as well in the real world as it did in clinical trials?
Does it matter if you've taken a GLP-1 drug before starting tirzepatide?
Read the original research
Association of tirzepatide with glycaemic control and weight loss in a real world cohort of patients with type 2 diabetes from the United States.
Diabetes, obesity & metabolism, 27(6), 3453-3463
Citation
Mody, Reema; Desai, Karishma; Teng, Chia-Chen; Reznor, Gally; Stockbower, Grace; Grabner, Michael; Benneyworth, Brian D. (2025). Association of tirzepatide with glycaemic control and weight loss in a real world cohort of patients with type 2 diabetes from the United States.. Diabetes, obesity & metabolism, 27(6), 3453-3463. https://doi.org/10.1111/dom.16372